TrialAnnals of oncology : official journal of the European Society for Medical Oncology2020

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

J K Litton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.